Subscribe X
Back to Top


September 14, 2018 by Megan Brooks | Medscape

ADHD Boosts Risk of Early-Onset Parkinson’s, Other Diseases

(Medscape) – Having attention-deficit/hyperactivity disorder (ADHD) may raise the risk developing Parkinson’s disease (PD) and related disorders, results of a population-based study suggest.

Investigators found that patients with ADHD were more than twice as likely to develop early-onset Parkinson’s and PD-related disorders relative to matched individuals who did not have ADHD. The risk was sixfold to eightfold higher in ADHD patients prescribed stimulant medications.

“This link between ADHD and its treatment with psychostimulants and Parkinson’s disease–like disorders (PDLDs) has not been shown before,” senior author Glen Hanson, PhD, professor of pharmacology and toxicology, University of Utah, Salt Lake City, told Medscape Medical News.

“That there is a link between pediatric mental health problems (eg, ADHD) and their treatment (eg, stimulants) and neurodegenerative diseases (eg, PDLDs) that typically express in older, and even geriatric, populations is a relatively new and somewhat disturbing concept,” said Hanson.

The study was published online September 12 in Neuropsychopharmacology.

Side Effect of Stimulants?

The investigators examined associations between ADHD and PD and related disorders using the Utah Population Database (UPDB).

They created a cohort of 31,769 individuals who had a history of ADHD, of whom 4960 were treated with stimulant medications, and a non-ADHD comparison cohort of 158,790 individuals matched (5:1) for sex and age.

None of the participants had a prior diagnosis of PD or related disorders of the basal ganglia and cerebellum or a history of substance abuse. All participants were at least 20 years old in 2011. The development of PD and related disorders was tracked until age 60 years.

In the ADHD cohort, the rate of incident PD and related diseases was 0.52%, compared with 0.19% in the non-ADHD cohort. The median age at disease onset was slightly younger in the ADHD than the non-ADHD cohort (43 years vs 45 years).

Overall, ADHD was associated with a 2.4-fold increased risk for PD and related diseases (adjusted hazard ratio [aHR], 2.4; 95% confidence interval [CI], 2.0 – 3.0; P < .0001), the research team found.

The risk was significantly higher in ADHD patients who took stimulants (aHR, 6.0; 95% CI, 3.9 to 9.1; P < .0001) than it was for those who had not taken stimulants (aHR, 1.8; 95% CI, 1.4 – 2.3; P < .0001).

ADHD patients who were only prescribed methylphenidate had an eightfold increased risk for PD and related diseases compared to persons who did not have ADHD (aHR, 8.0; 95% CI, 4.2 – 15.1; P < .0001).

In their article, the researchers caution that it may be that the apparent association between being prescribed stimulant medication and being at higher risk for PD and related diseases is a result of the fact that the phenotype of patients who are prescribed stimulant medication is more severe than that of persons who are not prescribed a stimulant, rather than a direct association between prescribed stimulant use and these diseases.

“The jury is still out. The increased risk we observed in people could be linked to having ADHD itself or perhaps a more severe form of ADHD, which may be more likely to be treated with medications,” first author Karen Curtin, PhD, from the University of Utah, said in a news release.

She also noted that the absolute risk of developing PD remained low. “If we were to follow 100,000 adults prescribed treatment for ADHD over time, we estimate that over a year, eight to nine patients will develop Parkinson’s disease before age 50,” she noted. By comparison, in a population of 100,000 persons who did not have ADHD, one to two would develop PD.

Prior studies provide some support for their findings. Preclinical studies have shown that exposure to high doses of amphetamine or its analogue, methamphetamine, causes persistent basal ganglia dopaminergic deficits. In clinical studies, basal ganglia dopaminergic deficits have been found in people who have a history of methamphetamine abuse, which is of “particular interest,” given epidemiologic reports that people who abuse amphetamine/methamphetamine are more likely to develop PD, the researchers say.

In addition, in a prior study using the UPDB, they found that individuals with a history of amphetamine/methamphetamine abuse were two to three times more likely to develop PD or related disorders.

More Study Needed

The researchers note the current results should be considered preliminary. One limitation of the study is that it is possible that persons may have been misclassified as not having ADHD. Such misclassification could have occurred as a result of individuals being diagnosed with the disorder in a state other than Utah, or as a result of missed or incorrect diagnosis of PD-like disease, or through the lack of information on the duration of use and dosage of ADHD medication prescribed, they point out.

Nonetheless, Hanson said the findings have several “important clinical implications.”

“First, our findings suggest that a significant fraction of patients who develop PDLD have a history of ADHD with stimulant treatment. Perhaps by studying this ADHD population we can discover some important causative factors for PDLDs that can lead to be treatment or even prevention,” he explained.

“Second, if it is determined that treatment of ADHD with the psychostimulants is responsible for the substantial increase in PDLD expression in ADHD patients (going from a 2.3-fold to an 8.6-fold increase), it would be very important to find other drugs to treat ADHD that do not have this side effect,” he said.

“Finally, while our findings absolutely do not mean that ADHD patients should no longer be treated with the stimulant drugs if needed, hopefully it would be considered in the benefit/risk discussion for deciding the best approach for managing these persons,” said Hanson.

The study was supported by the Huntsman Cancer Foundation. The UPDB is supported by the University of Utah ‘ s Program in Personalized Health and the Center for Clinical and Translational Science. The authors have disclosed no relevant financial relationships.

Neuropsychopharmacol. Published online September 12, 2018. Abstract



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
  • 1boringoldman


    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.